Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib + FOLFOX in Advanced Gastric/GEJ Cancer
NCT00982592Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vismodegib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by National Cancer Institute. Primary endpoint: Median Progression-free Survival up to 4 years. Started Sep 2009; status: completed.
02
Drugs
vismodegib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00982592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982592.